Rachel Condjella, Executive Director, Therapuetic Strategy, Oncology at Worldwide Clinical Trials, shared on LinkedIn:
“I’m happy to share that I’m starting a new position as Executive Director, Therapuetic Strategy, Oncology at Worldwide Clinical Trials.”
Worldwide Clinical Trials and Oncology Expertise
- Worldwide Clinical Trials positions itself as a specialized global oncology CRO, supporting sponsors from first-in-human studies through regulatory approval. Its model is designed around the scientific and operational complexity of cancer research, helping sponsors initiate studies, progress development programs, and expand internationally while maintaining continuity, specialist expertise, and access to senior leadership throughout the program.
- Oncology trials require tailored support because early studies enroll patients rather than healthy volunteers, eligible populations may be small or biomarker-defined, and standards of care evolve. Worldwide highlights its reach across more than 70 countries, oncology knowledge across operational functions, and team retention above 90%.
- The company supports a broad range of cancer indications and treatment modalities, including solid tumors, hematologic malignancies, and rare cancers, as well as immuno-oncology, antibody-drug conjugates, and cell and gene therapies.
You may also be interested in:
Danielle Lebowitz: Thrilled to Start a New Position as Cancer Genetic Counselor at MSK